Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Patients with hematological malignancies (HMs) are at higher risk of severe COVID-19 and secondary infections, which further complicate their outcomes. This study evaluated the impact of secondary infections (SIs) on mortality in hospitalized HM patients with SARS-CoV-2 infection and identified risk factors associated with SIs. We included 217 patients with HMs and COVID-19 admitted to a tertiary hospital in Rome, from April 2020 to September 2022. SIs occurred in 44.2% of patients, with bloodstream infections (42.7%) and respiratory infections (30.5%) being most frequent; among the latter, COVID-19-associated pulmonary aspergillosis (CAPA) was observed in 41.4% of cases. Viral reactivations, predominantly CMV, occurred in 9.2% of patients. The overall mortality rate was 29%, with higher mortality observed in patients with SIs (47.4% vs. 14.7%, < 0.01). Risk factors for SIs included severe COVID-19 (OR = 2.957, < 0.05) and prolonged hospitalization (OR = 1.095, < 0.001). Severe COVID-19 (OR = 8.229, < 0.001), intensive care unit (ICU) admission (OR = 15.232, < 0.001), chronic steroid therapy (OR = 2.803, < 0.05), SIs (OR = 2.892, < 0.05), and viral reactivation (OR = 6.269, < 0.01) were independent predictors of mortality. SIs and viral reactivations are common in patients with HMs and SARS-CoV-2 infection and significantly increase mortality, highlighting the need for timely management and preventive strategies in this vulnerable population.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861615PMC
http://dx.doi.org/10.3390/v17020274DOI Listing

Publication Analysis

Top Keywords

secondary infections
12
sars-cov-2 infection
12
severe covid-19
12
patients
8
patients hematological
8
hematological malignancies
8
risk factors
8
sis included
8
patients hms
8
viral reactivations
8

Similar Publications

Objective: Determine whether acute kidney injury (AKI) is associated with subsequent late-onset infection (LOI) among extremely low gestational age newborns (ELGAN).

Study Design: Secondary analysis of participants in the Preterm Erythropoietin for Neuroprotection Trial. Infants surviving ≥7 days with sufficient serum creatinine data were included.

View Article and Find Full Text PDF

Objective: To externally validate the Paediatric Emergency Care Applied Research Network (PECARN) rule for identifying febrile infants aged <60 days at low risk of serious bacterial infections (SBIs) and assess the utility of the rule with C reactive protein (CRP) instead of procalcitonin (PCT).

Methods: Secondary analysis of data from the Management and Outcomes of Fever in Children in Europe (MOFICHE) study (12 paediatric emergency departments in eight European countries, January 2017 to April 2018) and a Swedish study (four paediatric emergency departments, January 2014 to December 2020). Previously healthy febrile infants aged ≤60 days were included.

View Article and Find Full Text PDF

Objectives: Canadian guidelines recommend HIV testing for individuals being evaluated for syphilis. Our objective was to examine three aspects of HIV testing (ie, if an HIV test occurred, the timing of the HIV test in relation to the syphilis test and the proportion with a positive HIV test result) among syphilis tests between 2017 and 2022 from individuals with no evidence of a previous HIV diagnosis.

Design And Setting: This study is a retrospective analysis of comprehensive laboratory testing data from Ontario's provincial public health laboratory.

View Article and Find Full Text PDF

Pediatric bronchiectasis action management plan to improve clinical outcomes: An RCT.

Chest

September 2025

Child and Maternal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia; School of Nursing and Midwifery, Charles Darwin University, Darwin, Northern Territory, Australia.

Background: Managing bronchiectasis exacerbations is a priority for patients/parents/caregivers of children with bronchiectasis, yet evidence-based strategies among the pediatric population remain limited.

Research Question: Does the use of a personalized, written bronchiectasis action management plan (BAMP), compared to standard care, reduce non-scheduled doctor visits among children/adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis?

Study Design And Methods: Our multicenter, double-blind, superiority, randomized controlled trial enrolled children from three Australian respiratory departments between June 2018 and December 2020. Children/adolescents aged <19 years with CSLD/bronchiectasis were randomized to receive a personalized BAMP (intervention) or standard care (controls).

View Article and Find Full Text PDF

Results of TOR001: an open-label single patient study using targeted bacteriophage therapy for the treatment of a chronic urinary tract infection.

Int J Antimicrob Agents

September 2025

Unity Health Toronto, St. Joseph's Health Centre, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Unity Health Toronto, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada. Electronic address: Gregory.German@unityhe

Chronic urinary tract infections are persistent bacterial infections with the potential to drive antibiotic resistance. Like other persistent bacterial infections, intracellular bacterial reservoirs and biofilm formation hinder the clearance of pathogens despite long courses of antibiotic therapy. New strategies for treatment of these persistent infections are needed.

View Article and Find Full Text PDF